Urology

Focal Therapy and Interventional Urology

Our interventional urology program, led by Ardeshir R. Rastinehad, DO,  strives to cultivate and develop a multidisciplinary program by integrating urological knowledge standing with new imaging technologies and interventional radiological skills to improve urologic patient care. The interventional urology team includes interventional radiologists Aaron Fischman, MD and Gajan Sivananthan, MD.  Our team approach helps us research and develop new therapies to move them as efficiently as possible from the research bench to mainstream clinical practice.

Interventional urology provides care for many urologic conditions in the most minimally invasive fashion possible.  New approaches include state-of-the-art prostate cancer screening technologies, focal therapies for prostate cancer, minimally invasive kidney cancer treatments, embolization for benign prostate hyperplasia (BPH), and non-surgical approaches to treat varicoceles and erectile dysfunction.

Research Summary

Dr. Rastinehad is the world’s first dual fellowship-trained urologic oncologist and interventional radiologist. His oncology research focused on image optimization for prostate cancer screening and treatment. He pioneered development of the first electromagnetically tracked magnetic resonance ultrasound fusion biopsy platform to perform transperineal biopsies, which offers a lower morbidity rate than the standard transrectal biopsy approach. Using the image-based biopsy platform (the first U.S. Food and Drug Administration-cleared device for guidance for focal therapy), he performed the world’s first gold nano-particle directed laser ablation for prostate cancer. Dr. Rastinehad continues to push the field forward with multiple extra-mural collaborations with investigators from the National Institutes of Health, Case Western Reserve University, and the Smith Institute for Urology.

Dr. Rastinehad continues to develop therapies for benign urologic diseases as well. He has extensive experience in performing prostate artery embolizations for the treatment of BPH. Almost all urologic treatments of BPH have negative sexual side effects and affect quality of life, but prostate artery embolization does not have any of these sequelae. Generally, patients report improvement in their erections.

Mount Sinai Firsts

At Mount Sinai, we have made—and continue to make—groundbreaking contributions to the field of urology. Here are some of our “firsts”:

  • First textbook on interventional urology
  • First magnetic resonance imaging/ultrasound fusion-guided tansperineal biopsy using electromagnetic tracking
  • Frist in the world: magnetic resonance imaging/ultrasound fusion-guided gold nanoparticle- directed laser ablation of prostate cancer
  • First dual fellowship-trained urologic oncologist and interventional radiologist
  • First in the world magnetic resonance imaging/ultrasound fusion-guided prostate biopsy course in collaboration with the American Urological Association